IFx-Hu2.0
- Generic Name
- IFx-Hu2.0
- Drug Type
- Biotech
- Background
IFx-Hu2.0 is an investigational cancer vaccine. It is composed of plasmid DNA encoding the streptococcal membrane protein, Emm55, contained within a cationic polymer.
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Patients With Advanced Or Metastatic Merkel Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Advanced Or Metastatic Merkel Cell Carcinoma
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT06947928
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Phase 1
Not yet recruiting
- Conditions
- Advanced Or Metastatic Merkel Cell Carcinoma
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT06940440
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
Phase 1
Active, not recruiting
- Conditions
- Non-Melanoma Skin CancersMerkel Cell CarcinomaCutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04160065
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath